Breaking News, Financial News

Financial Report: Emergent BioSolutions

Cangene ops boost revenue in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions 2Q Revenues: $110.3 million (+34%) 2Q Earnings: $5.0 million (+51%) YTD Revenues: $164.2 million (+31%) YTD Loss: $15.2 million (earnings were $2.4 million YTD13) Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to hi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters